| Ytd | -9.81% | |
| 1y | -58.02% |
| Open | 5.02 | Prev Close | 4.64 | Low | 4.66 | High | 5.02 | Mkt Cap | 6.92M |
| Vol | 2.65K | Avg Vol | 1.45M | EPS | -24.12 | P/E | N/A | Forward P/E | -0.28 |
| Beta | 1.05 | Short Ratio | 0.04 | Inst. Own | 0.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 4.68 | 200-d Avg | 5.51 | 1yr Est | 0.50 |
CNSP News
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NA
Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceutica
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp t
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(7.30) per share which missed the an
Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differen
CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Wednesday's premarket session.
CNS Pharmaceuticals plans a pivot to an acquisition-led strategy, capital raise, and technicals sign
US stocks traded lower with Dow down 0.4%. NASDAQ up 0.07% while S&P 500 fell 0.03%. Norwegian C
US stocks fell, Dow dropped 150 points. Dow at 49,321.96, NASDAQ at 25,109.76, S&P 500 at 7,223.
CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Monday's premarket session following the
CNS Pharmaceuticals announces $22.5 million financing as the company pivots its strategy, eyes asset
The private placement includes participation from institutional healthcare investors, including ADAR
EBAY: 13% | GameStop's Cohen Threatens Proxy War In High-Stakes eBay Bid CNSP: 165% | CNS Pharma
The private placement includes participation from several leading healthcare investors including ADA
Newly formed executive team initiates global search for differentiated therapeutic assets for neurol
Newly formed executive team initiates global search for differentiated therapeutic assets for neurol
Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience s
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001729427/000168316826001066/cns_8k.htm
New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optim
Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CN
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutica
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutica
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCE
CNS Pharmaceuticals, Inc. ( CNSP ) Shareholder/Analyst Call November 17, 2025 12:00 PM EST Company P
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(5.76) per share which beat the anal
Cash expected to fund operations into the second half of 2026 Company focused on advancing next-gene
HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" o
Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announc
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" o
Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Drivi
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(6.42) per share which beat the anal
- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14
– Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmac
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutica